Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trial

• Main Authors: Pengfei Jin (Author), Qiao Liu (Author), Wenli Chen (Author), Xilin Guo (Author), Hongmei Jiang (Author), Ruimei Zhang (Author), Mingdong Ding (Author), Kui Zhang (Author), Zhaolan Cao (Author), Jiexiao He (Author), Siyue Jia (Author), Mingwei Wei (Author), Yuansheng Hu (Author), Lunbiao Cui (Author), Jianfeng Wang (Author), Zhuopei Li (Author), Xiaoyin Zhang (Author), Xin Xia (Author), Yanfei Wu (Author), Li Zhou (Author), Yawen Zhu (Author), Chunjing Gao (Author), Tiantian Zhang (Author), Fengcai Zhu (Author), Gang Zeng (Author), Limei Zhu (Author), Jingxin Li (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background To assess the immunogenicity and safety of two-dose regimen of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis (PTB) and explored the potential benefits of additional dose.Research design and methods In total, 182 PTB patients were randomly (1:1) assigned to the stan...